{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:37:22Z","timestamp":1790005042463,"version":"4.0.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T00:00:00Z","timestamp":1399939200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0096187","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T20:41:11Z","timestamp":1400013671000},"page":"e96187","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Simplification to Abacavir\/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01102972","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David A.","family":"Wohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laveeza","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry H.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winkler G.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Shaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/phar.1205","article-title":"Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-na\u00efve","volume":"33","author":"RJ Bertz","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref2","unstructured":"Johnson VA, Calvez V, G\u00fcnthard HF, Paredes R, Pillay D, <etal>et al<\/etal>.. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med; Epub before print."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e49289","DOI":"10.1371\/journal.pone.0049289","article-title":"Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study","volume":"7","author":"L Hocqueloux","year":"2012","journal-title":"PLoS One"},{"key":"ref4","unstructured":"Prescribing information for Norvir. North Chicago, IL: AbbVie Inc., January 2013."},{"key":"ref5","unstructured":"Prescribing information for Reyataz. Princeton, NJ: Bristol-Meyers Squibb, April 2013."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1310\/hct1103-170","article-title":"Simplified maintenance therapy with abacavir\/lamivudine and atazanavir after discontinuation of ritonavir","volume":"11","author":"R Elion","year":"2010","journal-title":"HIV Clin Trials"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424\u2013097) 48-week results","volume":"44","author":"J Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3851\/IMP1666","article-title":"Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as ritonavir-boosted regimen","volume":"15","author":"J Ghosn","year":"2010","journal-title":"Antivir Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/jac\/dkr316","article-title":"Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virologic suppression under antiretroviral therapy","volume":"66","author":"J Pavie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1310\/hct1003-129","article-title":"Unboosted atazanavir plus co-formulated lamivudine\/abacavir as a ritonavir-sparing simplification study in routine clinical practice","volume":"10","author":"JR Santos","year":"2009","journal-title":"HIV Clin Trials"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAI.0b013e3181a5701c","article-title":"Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir","volume":"51","author":"M Sension","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkm413","article-title":"Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viremia: final results of the SLOAT trial","volume":"61","author":"V Soriano","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/QAD.0b013e32833bee1b","article-title":"Similar efficacy and tolerability of atazanavir compared with atazanavir\/ritonavir, each with abacavir\/lamivudine after initial suppression with abacavir\/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients","volume":"24","author":"KE Squires","year":"2010","journal-title":"AIDS"},{"key":"ref14","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf<\/ext-link>. Accessed April 10."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"AS Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"RB D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)","volume":"285","author":"Detection Expert Panel on","year":"2001","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen","volume":"51","author":"TT Brown","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients: a 3-year randomized trial","volume":"292","author":"JE Gallant","year":"2004","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"GA McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"H Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3851\/IMP1874","article-title":"Bone turnover, osteoprotegerin\/RANKL and inflammation with antiretroviral initiation: tenofovir vs non-tenofovir regimens","volume":"16","author":"TT Brown","year":"2011","journal-title":"Antivir Ther"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2334-12-38","article-title":"Prospective evaluation of bone markers, parathormone, and 1,25-(OH)<sub>2<\/sub> vitamin D in HIV-positive patients after the initiation of tenofovir\/emtricitabine with atazanavir\/ritonavir or efavirenz","volume":"12","author":"E Foca","year":"2012","journal-title":"BMC Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/QAI.0b013e31820cf010","article-title":"Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used","volume":"56","author":"RJ Piso","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e38377","DOI":"10.1371\/journal.pone.0038377","article-title":"Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine","volume":"7","author":"H Haskelberg","year":"2012","journal-title":"PLoS ONE"},{"key":"ref26","first-page":"e32445","article-title":"Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial PLoS ONE","volume":"7","author":"TA Rasmussen","year":"2012"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/135965350701200812","article-title":"Tenofovir use is associated with a reduction in the calculated glomerular filtration rate in the Swiss HIV cohort study","volume":"12","author":"CA Fux","year":"2007","journal-title":"Antivir Ther"},{"key":"ref28","unstructured":"Ryom L, Mocroft A, Worm SW, Kamara DA, Reiss P, et al. Exposure to antiretrovirals (ARVs) and the risk of renal impairment among HIV+ persons with normal baseline renal function: the D:A:D study. Program and abstracts of the 19th Conference on Retroviruses and Opportunistic Infections, March 5\u20138, 2012; Seattle, WA: Poster 865."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","article-title":"Randomized, double-blind, placebo-matched multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment","volume":"23","author":"KY Smith","year":"2009","journal-title":"AIDS"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1\u2013infected adults: 48-week results from the ASSERT study","volume":"55","author":"FA Post","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-6405-7-9","article-title":"Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir","volume":"7","author":"E Jong","year":"2010","journal-title":"AIDS Res Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1097\/QAD.0b013e32833f147f","article-title":"Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial","volume":"24","author":"A Martin","year":"2010","journal-title":"AIDS"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32833562c5","article-title":"Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction","volume":"24","author":"E Martinez","year":"2010","journal-title":"AIDS"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3851\/IMP2020","article-title":"Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction","volume":"17","author":"P Patel","year":"2012","journal-title":"Antivir Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/aid.2012.0278","article-title":"Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir\/lamivudine\/atazanavir with or without ritonavir in ARIES","volume":"29","author":"B Young","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref36","first-page":"1637","article-title":"SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine\/tenofovir from lamivudine\/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis","volume":"56","author":"R Campo","year":"2013"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0103925","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T00:00:00Z","timestamp":1406073600000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0096187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T03:03:48Z","timestamp":1689217428000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0096187"}},"subtitle":[],"editor":[{"given":"D. William","family":"Cameron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,13]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0096187","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0103925","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,13]]}}}